Alnylam Pharmaceuticals Inc (DUL.BE)
Chart Events
Performance Outlook
| Previous Close | 173.48 |
| Open | 174.78 |
| Bid | 179.50 x N/A |
| Ask | 181.04 x N/A |
| Day's Range | 174.78 - 179.34 |
| 52 Week Range | 113.36 - 230.45 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Apr 26, 2023 - May 01, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for DUL.BE
Related Research
- American City Business Journals
Alnylam CEO Yvonne Greenstreet sees growing the company as 'a wonderful challenge'
When Greenstreet joined the drugmaker as chief operating officer in 2016, it had yet to turn its RNA-silencing technology into commercial drugs. Now, it's a nine-figure company.
- Zacks
Strength Seen in Halozyme Therapeutics (HALO): Can Its 5.3% Jump Turn into More Strength?
Halozyme Therapeutics (HALO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- InvestorPlace
3 Growth Stocks That Could Disrupt the Healthcare Industry
Healthcare growth stocks are often sought out by investors looking for market disruptors. That’s because these stocks can potentially deliver high revenue growth, earnings, and stock price. As an evolving sector, the healthcare industry is seeing high demand for innovative solutions to high patient costs and technology-driven efficiency. Examples of healthcare growth stocks include pharmaceutical companies developing new drugs, medical device manufacturers creating innovative devices, and health
